Session Synopsis: Enabling the oncology community to harness the power of clinical data and electronic health care records to improve standard care requires data sharing, aggregation, and harmonization of research-grade datasets, including a supportive infrastructure. This session focuses on recent developments that enable clinical workflow acceleration and decision making for precision medicine.
Session Chair Profile
M.D., Ph.D., Associate Professor, UNC-Chapel Hill
Dr. Berg is an Assistant Professor in the Department of Genetics at the University of North Carolina at Chapel Hill. He also has a clinical appointment in the Department of Medicine, Division of Hematology-Oncology and the Lineberger Comprehensive Cancer Center. He graduated from Emory University with a B.S. in Biology and completed the M.D./Ph.D. program at the University of North Carolina at Chapel Hill in the Curriculum in Neuroscience. He subsequently underwent residency training in Clinical Genetics at Baylor College of Medicine.
Taking Genomic Sequencing from Diagnosis to Screening
Genomic sequencing offers an unprecedented opportunity to establish molecular etiologies in patients with hereditary conditions. However, why should we wait until someone becomes sick to identify the cause? Predictive sequencing for monogenic disorders has tremendous promise, but we need to recognize the limitations and pitfalls to ensure evidence-based genomic medicine.
M.D., Ph.D., Chief Medical Officer and Chief Scientific Officer of Flatiron Health
Amy P. Abernethy, MD PhD is the Chief Medical Officer and Chief Scientific Officer at Flatiron Health, a healthcare technology company focused on organizing the world’s cancer data and making it actionable for providers, patients, researchers and life sciences. At Flatiron, Dr. Abernethy leads the Oncology and Science parts of the organization. She is a hematologist/oncologist and palliative medicine physician, and internationally recognized cancer clinical researcher with over 400 publications. Dr. Abernethy is an appointee to the National Academy of Medicine’s (formerly the Institute of Medicine) National Cancer Policy Forum, on the Executive Board for the Personalized Medicine Coalition, and Past President of the American Academy of Hospice & Palliative Medicine. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. She is also on the Board of Directors of athenahealth, Inc.
Clinico-Genomics: What is it and Why do we need it?
In this session, Dr. Abernethy will explore what happens when we are able to combine real-world clinical evidence from the patient’s medical record with their genomic analysis. Insights and findings will be shared — discoveries previously only made possible through clinical trials or patient registries.